Sanofi (NYSE:SNY) said today that the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended its insulin lispro biosimilar for approval.
Insulin lispro Sanofi is a biosimilar of insulin lispro, a fast-acting insulin analog made using recombinant DNA technology. Sanofi’s biosimilar has the exact same amino acid sequence as its reference product. The positive opinion from CHMP is Sanofi’s 1st major regulatory win for a biosimilar diabetes treatment.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi’s insulin biosimilar wins EMA committee recommendation appeared first on MassDevice.